NVS saved Peptimmune from bankruptcy about a year ago in return for an exclusive option on PI-2301, the Copaxone-like drug (#msg-34865448). However, I had heard nothing about this program since the NVS deal until I read your post, which curiously does not mention NVS.
I’ll add an entry about PI-2301 in the MNTA ReadMeFirst.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”